A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk. Results from a Phase 2b clinical trial, published today in The Lancet by researchers led by King’s College London, provide hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonizing chronic inflammatory disease.
This article was originally published on MedicalXpress.com
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
© 2024 SimplyWell.ca